Biochips Global Market Report 2024

The biochips market size has grown rapidly in recent years. It will grow from $10.86 billion in 2023 to $12.62 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. During the historic period, growth can be attributed to various factors, including the rising demand for personalized medicine, the widespread prevalence of chronic diseases, continuous technological innovations, expanded applications in drug discovery, increased investments in research and development, and supportive regulatory frameworks.

The biochips market size is expected to see rapid growth in the next few years. It will grow to $23.18 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. In the forecast period, growth can be attributed to increasing adoption in point-of-care diagnostics, expanding applications in drug development, rising demand for personalized medicine, advancements in microfluidics technology, growing investments in research and development, expanding collaborations between biotechnology companies and academic institutions, and emerging opportunities in agricultural biotechnology. Major trends in this period include advancements in microfluidics technology, a focus on developing biochips for liquid biopsy applications, rising demand for multiplexed assays for simultaneous detection of multiple analytes, integration of artificial intelligence for data analysis, and the emergence of novel biochip platforms.

The biochips market is poised for growth due to the increasing adoption of personalized medicines. Personalized medicine involves tailoring medical treatments based on individual characteristics such as genetics or lifestyle, aiming to optimize effectiveness and minimize adverse effects. This trend is fueled by the potential of personalized medicine to offer more effective treatments, advancements in genomics, the rising complexity of diseases, and regulatory backing. Biochips play a crucial role in personalized medicine by enabling precise and individualized treatment plans based on a person's genetic profile. For instance, in February 2024, the FDA approved 16 novel personalized therapies for rare diseases in 2023, highlighting the momentum in personalized medicine adoption and its impact on the biochips market.

Leading companies in the biochips market are focusing on developing cutting-edge technologies such as organ-on-a-chip platforms to transform drug discovery and development processes. Organ-on-a-chip platforms are sophisticated microfluidic devices designed to mimic the physiological characteristics and functions of human organs on a smaller scale. For example, in April 2024, Boston Micro Fabrication (BMF) launched BMF Biotechnology Inc., specializing in biochips or organ-on-a-chip platforms for cultivating large-scale tissues in vitro. This advancement accelerates drug and cosmetic development by providing a testing and research platform outside the human body.

In June 2023, Randox Laboratories acquired Cellix Limited to bolster its expertise in benchtop flow cytometry, aligning with its commitment to personalized medicine and improved preventive healthcare. This acquisition expands Randox's portfolio and makes flow cytometry technology more accessible to a wider range of researchers and healthcare professionals. Cellix Limited, based in Ireland, specializes in creating biochips for various applications in the life sciences.

Major companies operating in the biochips market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd, Zoetis Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Tecan Group Ltd., Cepheid Inc., Randox Laboratories Ltd., Takara Bio Inc., Oxford Nanopore Technologies plc, Luminex Corporation, Fluidigm Corporation, Micronit Microtechnologies B.V., Sphere Fluidics Limited, Sengenics, Arrayit Corporation, CustomArray Inc., Partek Incorporated, NanoCellect Biomedical Inc., Dolomite Microfluidics, Biocartis NV.

North America was the largest region in the biochips market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biochips market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the biochips market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biochips are compact devices containing an assortment of biological substances such as DNA, proteins, or cells, affixed onto a solid surface. They merge biological components with electronic systems for studying and manipulating biological data, finding extensive use in medical diagnostics, genetic sequencing, and other biotechnological domains.

The primary types of biochips include DNA chips (or DNA microarrays), protein chips, lab-on-chip systems, tissue arrays, and cell arrays. DNA chips allow the simultaneous analysis of numerous genes' expressions, leveraging technologies such as microarrays and microfluidics. These biochips find applications in drug discovery, agriculture, genomics, disease diagnostics, proteomics, and are utilized by diverse end users such as biotech firms, pharmaceutical companies, academic institutions, hospitals, and diagnostic centers.

The biochips market research report is one of a series of new reports that provides biochips market statistics, including biochips industry global market size, regional shares, competitors with a biochips market share, detailed biochips market segments, market trends and opportunities, and any further data you may need to thrive in the biochips industry. This biochips market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biochips market consists of sales of lab-on-a-chip (LOC) devices, cellular microarrays, and protein microarrays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.